Aerogen’s aerosol drug delivery technology was used in Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults without COVID-19 from China, according to a company news release.

The Aerogen Solo is a closed-system, single-patient-use aerosol drug delivery technology1 that mitigates the transmission of patient-generated infectious aerosol during ventilation, according to the company.2-7

Hospitals around the world have been using Aerogen’s closed-circuit nebulizer technology to deliver aerosolized medication to critically ill ventilated COVID-19 patients, with over 3 million patients being treated with Aerogen in 20208.

The company formed a Covid response unit in March 2020 to support projects researching potential treatments and vaccines and is now working with global pharmaceutical companies on the safe delivery of inhaled therapies. Aerogen’s technology is being used in several clinical trials8. Details of the most recent trial being published this week in the Lancet.

Aerogen’s innovative aerosol drug delivery technology was used in a Phase 1 clinical trial to deliver inhaled type-5 vector-based COVID-19 vaccine (Ad5-nCoV) to adults without COVID-19 in China9. The Aerogen Ultra device was adapted to facilitate the study9.

The study concluded that the aerosol inhalation of Ad5-nCoV is painless, simple, well tolerated, and immunogenic, and the current data supports the evaluation of aerosolized Ad5-nCoV in ongoing phase 2 and 3 clinical trials9. The efficacy and cost-effectiveness of aerosol vaccination should be evaluated in future studies9.


References from Aerogen

  1. Aerogen Solo System Instruction Manual. Aerogen Ltd. P/N 30-354, Revision U.
  2. Ari A. Practical strategies for a safe and effective delivery of aerosolized medications to patients with COVID-19. Respir. Med. 2020; 167. doi:10.1016/j.rmed.2020.105987.
  3. Miller A, Epstein D. Safe bronchodilator treatment in mechanically ventilated COVID19 patients: A single center experience. J. Crit. Care. 2020; 58: 56–57.
  4. Fink JB, Ehrmann S, Li J, Dailey P, McKiernan P, Darquenne C et al. Reducing Aerosol-Related Risk of Transmission in the Era of COVID-19: An Interim Guidance Endorsed by the International Society of Aerosols in Medicine. J Aerosol Med Pulm Drug Deliv 2020. doi:10.1089/jamp.2020.1615.
  5. Halpin DMG, Criner GJ, Papi A, Singh D, Anzueto A, Martinez FJ et al. Global Initiative for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease: The 2020 GOLD Science Committee Report on COVID-19 & COPD. Am J Respir Crit Care Med 2020. doi:10.1164/rccm.202009-3533SO.
  6. O’Toole C, McGrath JA, Joyce M, Bennett G, Byrne MA, MacLoughlin R. Fugitive Aerosol Therapy Emissions during Mechanical Ventilation: In Vitro Assessment of the Effect of Tidal Volume and Use of Protective Filters. Aerosol Air Qual Res 2020; 20. doi:10.4209/aaqr.2020.04.0176.
  7. Joyce M, McGrath JA, Mac Giolla Eain M, O’Sullivan A, Byrne M, MacLoughlin R. Nebuliser Type Influences Both Patient-Derived Bioaerosol Emissions and Ventilation Parameters during Mechanical Ventilation. Pharmaceutics 2021; 13: 199.
  8. Aerogen Internal data on File.
  9. Wu S, Huang J, Zhang Z, Wu J, Zhang J, Hu H et al. Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial. Lancet Infect Dis 2021; 0. doi:10.1016/S1473-3099(21)00396-0.